Details

Autor(en) / Beteiligte

• Kwon, Mi-Ri
• Park, Ji-Soo
• Ko, Eun-Jung
• Park, Jin
• Ju, Eun-Jin
• Shin, Seol-Hwa
• Son, Ga-Won
• Lee, Hye-Won
• Park, Yun-Yong
• Kang, Myoung-Hee
• Kim, Yeon-Joo
• Kim, Byeong-Moon
• Lee, Hee-Jin
• Kim, Tae-Won
• Kim, Chong-Jai
• Song, Si-Yeol
• Park, Seok-Soon
• Jeong, Seong-Yun

Titel

Ibulocydine Inhibits Migration and Invasion of TNBC Cells via MMP-9 Regulation

Ist Teil von

• International journal of molecular sciences, 2024-06, Vol.25 (11), p.6123

Ort / Verlag

Basel: MDPI AG

Erscheinungsjahr

2024

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Triple-negative breast cancer (TNBC) accounts for approximately 15–20% of all breast cancer types, indicating a poor survival prognosis with a more aggressive biology of metastasis to the lung and a short response duration to available therapies. Ibulocydine (IB) is a novel (cyclin-dependent kinase) CDK7/9 inhibitor prodrug displaying potent anti-cancer effects against various cancer cell types. We performed in vitro and in vivo experiments to determine whether IB inhibits metastasis and eventually overcomes the poor drug response in TNBC. The result showed that IB inhibited the growth of TNBC cells by inducing caspase-mediated apoptosis and blocking metastasis by reducing MMP-9 expression in vitro. Concurrently, in vivo experiments using the metastasis model showed that IB inhibited metastasis of MDA-MB-231-Luc cells to the lung. Collectively, these results demonstrate that IB inhibited the growth of TNBC cells and blocked metastasis by regulating MMP-9 expression, suggesting a novel therapeutic agent for metastatic TNBC.